US5451603A
Expired / Lapsed
US
⏱️ 0.0 years remaining
3,4-diarylchromans for treatment of dermatitis
Assignee: Zymogenetics Inc
•
Filing: 1993-03-11
•
Granted: 1995-09-19
•
Expires: 2013-03-11
Abstract
Abstract Methods for the treatment of dermatitis are disclosed wherein 3,4-diarylchromans and their pharmaceutically acceptable salts are formulated into medicaments, including oral and topical medicaments, and are administered to a patient suffering from dermatitis.
Inventors
- 👤 James R. Piggott
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 13:45
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/335; A61K31/35; A61K31/395; A61K31/40; A61P; A61P43/00
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
88 words
A method for treating dermatitis in a patient comprising administering to a patient suffering from dermatitis an effective amount of a composition comprising a compound of the formula ##STR4## or a pharmaceutically acceptable salt thereof, wherein: R1, R4 and R5 are individually hydrogen, hydroxy, halo, trifluoromethyl, lower alkyl, lower alkoxy or tertiary amino lower alkoxy; and R2 and R3 are individually hydrogen or lower alkyl, in combination with a pharmaceutically acceptable carrier, wherein said dermatitis is psoriasis, atopic dermatitis, photoeczematous dermatitis, primary irritant dermatitis or allergic contact dermatitis.
Claim 2
Independent Claim
88 words
A method for treating dermatitis in a patient comprising administering to a patient suffering from dermatitis an effective amount of a composition comprising a compound of the formula ##STR4## or a pharmaceutically acceptable salt thereof, wherein: R1, R4 and R5 are individually hydrogen, hydroxy, halo, trifluoromethyl, lower alkyl, lower alkoxy or tertiary amino lower alkoxy; and R2 and R3 are individually hydrogen or lower alkyl, in combination with a pharmaceutically acceptable carrier, wherein said dermatitis is psoriasis, atopic dermatitis, photoeczematous dermatitis, primary irritant dermatitis or allergic contact dermatitis.
Claim 3
Dependent Claim
27 words
A method according to claim 1 wherein R1 is lower alkoxy, R2 and R3 are lower alkyl, R4 is hydrogen and R5 is tertiary amino lower alkoxy.
Claim 4
Dependent Claim
10 words
A method according to claim 1 wherein R1 is methoxy.
Claim 5
Dependent Claim
12 words
A method according to claim 1 wherein R2 and R3 are methyl.
Claim 6
Dependent Claim
10 words
A method according to claim 1 wherein R4 is hydrogen.
Claim 7
Dependent Claim
10 words
A method according to claim 1 wherein R5 is ##STR5##
Claim 8
Dependent Claim
11 words
A method according to claim 1 wherein said compound is ##STR6##
Claim 9
Dependent Claim
11 words
A method according to claim 1 wherein said dermatitis is psoriasis.
Claim 10
Dependent Claim
21 words
A method according to claim 1 wherein said dermatitis is atopic dermatitis, photoeczematous dermatitis, primary irritant dermatitis or allergic contact dermatitis.
Claim 11
Dependent Claim
17 words
A method according to claim 1 wherein said composition is in a form suitable for topical administration.
Claim 12
Independent Claim
72 words
A method for inhibiting hyperproliferation of keratinocytes in a patient comprising administering to a patient a compound of the formula ##STR7## or a pharmaceutically acceptable salt thereof, wherein: R1, R4 and R5 are individually hydrogen, hydroxy, halo, trifluoromethyl, lower alkyl, lower alkoxy or tertiary amino lower alkoxy; and R2 and R3 are individually hydrogen or lower alkyl, in combination with a pharmaceutically acceptable carrier, in an amount sufficient to inhibit keratinocyte proliferation.
Claim 13
Independent Claim
72 words
A method for inhibiting hyperproliferation of keratinocytes in a patient comprising administering to a patient a compound of the formula ##STR7## or a pharmaceutically acceptable salt thereof, wherein: R1, R4 and R5 are individually hydrogen, hydroxy, halo, trifluoromethyl, lower alkyl, lower alkoxy or tertiary amino lower alkoxy; and R2 and R3 are individually hydrogen or lower alkyl, in combination with a pharmaceutically acceptable carrier, in an amount sufficient to inhibit keratinocyte proliferation.
Claim 14
Dependent Claim
27 words
A method according to claim 11 wherein R1 is lower alkoxy, R2 and R3 are lower alkyl, R4 is hydrogen and R5 is tertiary amino lower alkoxy.
Claim 15
Dependent Claim
22 words
A method according to claim 11 wherein R1 is methoxy, R2 and R3 are methyl, R4 is hydrogen and R5 is ##STR8##
Claim 16
Dependent Claim
11 words
A method according to claim 11 wherein said compound is ##STR9##
Claim 17
Dependent Claim
12 words
A method according to claim 11 wherein said compound is applied topically.
References Cited (Backward Citations)
US3340276A
Cited
US3822287A
Cited
US4362742A
Cited
US4447622A
Cited
US4851433A
Cited
US4742066A
Cited
US5015661A
Cited
US5298512A
Cited
US5248777A
Cited
WO1992006084A1
Cited
WO1992018481A1
Cited
WO1992020642A1
Cited
WO1993020058A1
Cited
WO1993020059A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-09-18 | 1999-03-20 | 1999-09-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-09-18 | 2003-03-20 | 2003-09-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-09-18 | 2007-03-20 | 2007-09-19 | $7700.00 | Window Closed / Lapsed |